Crystalys Therapeutics

“Crystalys Therapeutics raised $130M Series B for oral uric acid-reducing therapy, dotinurad.”

“Raised $130M Series B — one of the larger biotech rounds in the issue, led by Frazier Life Sciences with broad institutional participation.”